Structure
Afuresertib hydrochloride, Inhibitor
Afuresertib hydrochloride
Purity
100.00%
Synonyms
Afuresertib hydrochloride; inhibitor
Purity/Purification
100.00%
Form/Format
Solid. Powder
Solubility
DMSO: 100mg/mL (215.62mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C18H17Cl2FN4OS
SMILES
Cl.Cn1ncc(Cl)c1-c1cc(C(=O)NC(CN)Cc2cccc(F)c2)sc1Cl
CAS Number
1047645-82-8
Target & IC50
Akt1: ic50 0.08nM (Ki)
Akt2: ic50 2nM (Ki)
Akt3: ic50 2.6nM (Ki)
Akt
Akt2: ic50 2nM (Ki)
Akt3: ic50 2.6nM (Ki)
Akt
Cell Research
Cell confluence proliferation assay was performed using Incucyte ZOOM Live-Cell Imaging System. Briefly, ACC-MESO-4 and MSTO-211H cells were seeded in 12-well plates (cell density, 1 x 104cells/well) and were incubated for 24 hours at 37 degree C. Then, the cells were incubated with 0, 2, 5, or 10uMol/L afuresertib. During treatment, cell growth was monitored by recording phase images using the IncuCyte ZOOM Live-Cell Imaging System (magnification, x100)[1].
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
-80 degree C for 2 years in solvent
Structure
Structure
Related Product Information for Afuresertib hydrochloride, inhibitor
Afuresertib hydrochloride is an inhibitor of Akt kinase (Kis of 0.08/2/2.6nM for Akt1/Akt2/Akt3 respectively)
Product Categories/Family for Afuresertib hydrochloride, inhibitor
References
Yamaji M, Ota A, Wahiduzzaman M,et al.Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells[J].Cancer Med. 2017 Nov;6(11):2646-2659.
Yamaji M, Ota A, Wahiduzzaman M, et al. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells[J]. Cancer Medicine, 2017.
Yamaji M, Ota A, Wahiduzzaman M, et al. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells[J]. Cancer Medicine, 2017.
Melissa D, Ming-Chih C, Shu-Yun Z, et al. Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor[J]. Plos One, 2014, 9(6):e100880-.
Blagden SP, Hamilton AL, Mileshkin L,et al.Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.Clin Cancer Res. 2019 Mar 1;25(5):1472-1478.
Blagden SP, Hamilton AL, Mileshkin L,et al.Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.Clin Cancer Res. 2019 Mar 1;25(5):1472-1478.
Yamaji M, Ota A, Wahiduzzaman M, et al. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells[J]. Cancer Medicine, 2017.
Yamaji M, Ota A, Wahiduzzaman M, et al. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells[J]. Cancer Medicine, 2017.
Melissa D, Ming-Chih C, Shu-Yun Z, et al. Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor[J]. Plos One, 2014, 9(6):e100880-.
Blagden SP, Hamilton AL, Mileshkin L,et al.Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.Clin Cancer Res. 2019 Mar 1;25(5):1472-1478.
Blagden SP, Hamilton AL, Mileshkin L,et al.Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.Clin Cancer Res. 2019 Mar 1;25(5):1472-1478.
Similar Products
Product Notes
The Afuresertib hydrochloride (Catalog #AAA5758747) is an Inhibitor and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "Afuresertib hydrochloride, Inhibitor" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
